FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Steven Snapinn

Research Profile

Chemicals & Drugs

Procedures

Double-Blind Method

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Chunlei Ke; Beiying Ding; Qi Jiang; Steven M Snapinn
The issue of multiplicity in noninferiority studies.
Reynold Spector; Steven M Snapinn
Statins for secondary prevention of cardiovascular disease: the right dose.
Sverre E Kjeldsen; Richard B Devereux; Darcy A Hille; Paulette A Lyle; Björn Dahlöf; Stevo Julius; Jonathan M Edelman; Steven M Snapinn; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Steven Snapinn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Chunlei Ke; Beiying Ding; Qi Jiang; Steven M Snapinn
The issue of multiplicity in noninferiority studies.
Clinical trials (London, England) 2012;9(6):730-5.
2011: Reynold Spector; Steven M Snapinn
Statins for secondary prevention of cardiovascular disease: the right dose.
Pharmacology 2011;87(1-2):63-9.
2009: Sverre E Kjeldsen; Richard B Devereux; Darcy A Hille; Paulette A Lyle; Björn Dahlöf; Stevo Julius; Jonathan M Edelman; Steven M Snapinn; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Blood pressure 2009;18(6):348-61.
2008: Steven M Snapinn; Qi Jiang
Controlling the type 1 error rate in non-inferiority trials.
Statistics in medicine 2008;27(3):371-81.
2008: Steven M Snapinn; Qi Jiang
Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials.
Statistics in medicine 2008;27(3):382-91.
2007: Wouter B A Eijkelkamp; Zhongxin Zhang; Barry M Brenner; Mark E Cooper; Richard B Devereux; Björn Dahlöf; Hans Ibsen; William F Keane; Lars H Lindholm; Michael H Olsen; Hans-Henrik Parving; Giuseppe Remuzzi; Shahnaz Shahinfar; Steven M Snapinn; Kristian Wachtell; Dick De Zeeuw
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.
Journal of hypertension 2007;25(4):871-6.
2007: Steven M Snapinn; Qi Jiang
Responder analyses and the assessment of a clinically relevant treatment effect.
Trials 2007;8():31.
2006: Steven M Snapinn; Mon-Gy Chen; Qi Jiang; Tony Koutsoukos
Assessment of futility in clinical trials.
Pharmaceutical statistics 2006;5(4):273-81.
2006: Vernon Bonarjee; Annika Rosengren; Steven M Snapinn; Margaret K James; Kenneth Dickstein
Sex-based short- and long-term survival in patients following complicated myocardial infarction.
European heart journal 2006;27(18):2177-83.
2006: William F Keane; Zhongxin Zhang; Paulette A Lyle; Mark E Cooper; Dick De Zeeuw; Jean-Pierre Grunfeld; James P Lash; Janet B McGill; William E Mitch; Giuseppe Remuzzi; Shahnaz Shahinfar; Steven M Snapinn; Robert D Toto; Barry M Brenner
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.
Clinical journal of the American Society of Nephrology : CJASN 2006;1(4):761-7.
2006: Peter M Okin; Richard B Devereux; Eva Gerdts; Steven M Snapinn; Katherine E Harris; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Jonathan Edelman; Lars H Lindholm; Björn Dahlöf
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Circulation 2006;113(12):1588-96.
2006: Hans Ibsen; Michael H Olsen; Kristian Wachtell; Knut Borch-Johnsen; Lars H Lindholm; Carl E Mogensen; Björn Dahlöf; Steven M Snapinn; Ying Wan; Paulette A Lyle
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Diabetes care 2006;29(3):595-600.
2006: Kenneth Dickstein; Gilbert W Gleim; Steven M Snapinn; Margaret K James; John Kjekshus
The impact of morbid events on survival following hospitalization for complicated myocardial infarction.
European journal of heart failure 2006;8(1):74-80.
2005: Albert A Carr; Peter R Kowey; Richard B Devereux; Barry M Brenner; Björn Dahlöf; Hans Ibsen; Lars H Lindholm; Paulette A Lyle; Steven M Snapinn; Zhongxin Zhang; Jonathan Edelman; Shahnaz Shahinfar
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
The American journal of cardiology 2005;96(11):1530-6.
2005: Eigil Fossum; andreas moan; Sverre E Kjeldsen; Richard B Devereux; Stevo Julius; Steven M Snapinn; Jonathan Edelman; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Björn Dahlöf
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Journal of the American College of Cardiology 2005;46(5):770-5.
2005: Zhongxin Zhang; Shahnaz Shahinfar; William F Keane; Denise Ramjit; Tania Z Dickson; Gilbert W Gleim; Carl Erik Mogensen; Dick De Zeeuw; Barry M Brenner; Steven M Snapinn
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Journal of the American Society of Nephrology : JASN 2005;16(6):1775-80.
2005: Jessica L Mega; David A Morrow; Marc S Sabatine; Xue-Qiao Zhao; Steven M Snapinn; Peter M DiBattiste; C Michael Gibson; Elliott M Antman; Eugene Braunwald; Pierre Théroux
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
American heart journal 2005;149(5):846-50.
2005: thao huynh; Nicolo Piazza; Peter M DiBattiste; Steven M Snapinn; Ying Wan; Chantal Pharand; Pierre Theroux
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
International journal of cardiology 2005;100(1):73-8.
2005: Frej Fyhrquist; Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Darcy A Hille; Paulette A Lyle; Jonathan Edelman; Steven M Snapinn; Hans Wedel
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Hypertension 2005;45(4):580-5.
2005: Sverre E Kjeldsen; Paulette A Lyle; Jorge R Kizer; Björn Dahlöf; Richard B Devereux; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Katherine E Harris; Hans Wedel
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Journal of clinical hypertension (Greenwich, Conn.) 2005;7(3):152-8.
2005: Mika Lehto; Steven M Snapinn; Kenneth Dickstein; Karl Swedberg; Markku S Nieminen
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience.
European heart journal 2005;26(4):350-6.
2005: Jorge R Kizer; Björn Dahlöf; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Kristian Wachtell; Jonathan Edelman; Steven M Snapinn; Katherine E Harris; Richard B Devereux
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Hypertension 2005;45(1):46-52.
2004: Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Markku S Nieminen; Steven M Snapinn; Katherine E Harris; Peter Aurup; Jonathan Edelman; Hans Wedel; Lars H Lindholm; Björn Dahlöf
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
JAMA : the journal of the American Medical Association 2004;292(19):2343-9.
2004: Qi Jiang; Steven M Snapinn; Boris Iglewicz
Calculation of sample size in survival trials: the impact of informative noncompliance.
Biometrics 2004;60(3):800-6.
2004: Dick De Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steven M Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Circulation 2004;110(8):921-7.
2004: Michael A Blazing; James A de Lemos; Harvey D White; Keith A A Fox; Freek W A Verheugt; Diego Ardissino; Peter M DiBattiste; Joanne Palmisano; David W Bilheimer; Steven M Snapinn; Karen E Ramsey; Laura H Gardner; Vic Hasselblad; Marc A Pfeffer; Eldrin F Lewis; Eugene Braunwald; Robert M Califf
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2004;292(1):55-64.
2004: Peter M Okin; Richard B Devereux; Markku S Nieminen; Sverker Jern; Lasse Oikarinen; Matti Viitasalo; Lauri Toivonen; Sverre E Kjeldsen; Stevo Julius; Steven M Snapinn; Björn Dahlöf
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
Hypertension 2004;44(1):48-54.
2004: Dick De Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steven M Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Kidney international 2004;65(6):2309-20.
2004: Steven M Snapinn; Thomas Cook; Deborah Shapiro; Duane Snavely
The role of the unblinded sponsor statistician.
Statistics in medicine 2004;23(10):1531-3.
2004: Cong Chen; Steven M Snapinn
Separate modeling approaches for survival analysis with inaccurate covariate measurements.
Journal of biopharmaceutical statistics 2004;14(2):375-87.
2004: Christy Chuang-Stein; Corsee Sanders; Steven M Snapinn
An industry survey on current practices in the design and analysis of active control studies.
Journal of biopharmaceutical statistics 2004;14(2):349-58.
2004: Steven M Snapinn
Alternatives for discounting in the analysis of noninferiority trials.
Journal of biopharmaceutical statistics 2004;14(2):263-73.
2004: Stephen J Servoss; Ying Wan; Steven M Snapinn; Peter M DiBattiste; Xue-Qiao Zhao; Pierre Theroux; Ik-Kyung Jang; James L Januzzi
Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
The American journal of cardiology 2004;93(7):843-7.
2004: Aina Hognestad; Kenneth Dickstein; Eivind Myhre; Steven M Snapinn; John Kjekshus
Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure.
The American journal of cardiology 2004;93(5):603-6.
2004: David L DeMets; Robert M Califf; Dennis Dixon; Susan S Ellenberg; Thomas Fleming; Peter Held; Desmond Julian; Richard S. Kaplan; Robert Levine; James D Neaton; Milton Packer; Stuart Pocock; Frank Rockhold; Belinda Seto; Jay Siegel; Steven M Snapinn; David Stump; Robert Temple; Richard Whitley
Issues in regulatory guidelines for data monitoring committees.
Clinical trials (London, England) 2004;1(2):162-9.
2003: Kristian Wachtell; Hans Ibsen; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Peter M Okin; Per Omvik; Suzanne Oparil; Hans Wedel; Steven M Snapinn; Peter Aurup
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Annals of internal medicine 2003;139(11):901-6.
2003: Cong Chen; Hongwei Wang; Steven M Snapinn
Proportion of treatment effect (PTE) explained by a surrogate marker.
Statistics in medicine 2003;22(22):3449-59.
2003: thao huynh; Pierre Theroux; Steven M Snapinn; Ying Wan
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
American heart journal 2003;146(4):668-73.
2003: Lars H Lindholm; Björn Dahlöf; Jonathan Edelman; Hans Ibsen; Knut Borch-Johnsen; Michael H Olsen; Steven M Snapinn; Kristian Wachtell
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Lancet 2003;362(9384):619-20.
2003: Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Markku S Nieminen; Steven M Snapinn; Katherine E Harris; Peter Aurup; Jonathan Edelman; Bjorn Dahlof
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Circulation 2003;108(6):684-90.
2003: Richard B Devereux; Björn Dahlöf; Sverre E Kjeldsen; Stevo Julius; Peter Aurup; Gareth Beevers; Jonathan Edelman; Ulf de Faire; Frej Fyhrquist; Sigrid Helle Berg; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Hans Wedel
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Annals of internal medicine 2003;139(3):169-77.
2003: Krister Kristianson; Frej Fyhrquist; Richard B Devereux; Sverre E Kjeldsen; Lars H Lindholm; Paulette A Lyle; Markku S Nieminen; Steven M Snapinn
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Clinical therapeutics 2003;25(4):1186-99.
2003: William F Keane; Barry M Brenner; Dick De Zeeuw; Jean-Pierre Grunfeld; Janet McGill; William E Mitch; Artur B Ribeiro; Shahnaz Shahinfar; Roger L Simpson; Steven M Snapinn; Robert D Toto
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.
Kidney international 2003;63(4):1499-507.
2003: Christopher Heeschen; Christian W Hamm; Ulrich Laufs; Michael Böhm; Steven M Snapinn; Harvey D White
Withdrawal of statins in patients with acute coronary syndromes.
Circulation 2003;107(3):e27.
2002: Sverre E Kjeldsen; Björn Dahlöf; Richard B Devereux; Stevo Julius; Peter Aurup; Jonathan Edelman; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Hans Wedel
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
JAMA : the journal of the American Medical Association 2002;288(12):1491-8.
2002: Lars H Lindholm; Hans Ibsen; Knut Borch-Johnsen; Michael H Olsen; Kristian Wachtell; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven M Snapinn
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Journal of hypertension 2002;20(9):1879-86.
2002: James L Januzzi; Steven M Snapinn; Peter M DiBattiste; Ik-Kyung Jang; Pierre Theroux
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
Circulation 2002;105(20):2361-6.
2002: Christopher Heeschen; Christian W Hamm; Ulrich Laufs; Steven M Snapinn; Michael Böhm; Harvey D White
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Circulation 2002;105(12):1446-52.
2002: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven M Snapinn
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359(9311):1004-10.
2002: David A Morrow; Elliott M Antman; Steven M Snapinn; Carolyn H McCabe; Pierre Theroux; Eugene Braunwald
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
European heart journal 2002;23(3):223-9.
2001: HH Parving; B M Brenner; M E Cooper; D de Zeeuw; William F Keane; W E Mitch; G Remuzzi; Steven M Snapinn; Z Zhang; Shahnaz Shahinfar
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Ugeskrift for laeger 2001;163(40):5514-9.
2001: Barry M Brenner; M E Cooper; Dick De Zeeuw; William F Keane; W E Mitch; Hans-Henrik Parving; Giuseppe Remuzzi; Steven M Snapinn; Zhongxin Zhang; Shahnaz Shahinfar
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
The New England journal of medicine 2001;345(12):861-9.
2001: Marc S Sabatine; James L Januzzi; Steven M Snapinn; Pierre Théroux; Ik-Kyung Jang
A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris.
The American journal of cardiology 2001;88(5):488-92.
2000: Pierre Théroux; J Alexander; C Pharand; E Barr; Steven M Snapinn; A F Ghannam; FL Sax
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Circulation 2000;102(20):2466-72.
1999: X Q Zhao; Pierre Théroux; Steven M Snapinn; FL Sax
Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Circulation 1999;100(15):1609-15.
1999: L Tomasko; R W Helms; Steven M Snapinn
A discriminant analysis extension to mixed models.
Statistics in medicine 1999;18(10):1249-60.
1998: B A Deyi; A S Kosinski; Steven M Snapinn
Power considerations when a continuous outcome variable is dichotomized.
Journal of biopharmaceutical statistics 1998;8(2):337-52.
1998: Steven M Snapinn
Survival analysis with uncertain endpoints.
Biometrics 1998;54(1):209-18.
1994: T J Simon; M M Berenson; roger berlin; Steven M Snapinn; A Cagliola
Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis.
Alimentary pharmacology & therapeutics 1994;8(1):71-9.